torrent pharma

Affordable generic versions of Ozempic and Wegovy have quickly secured 20% of the Rs 1,600 crore weight-loss market following patent expiry. Early movers like Torrent and Sun Pharma are challenging Eli Lilly's Mounjaro, with generics and lower pricing boosting semaglutide's market position.

Indian pharmaceutical giants like Sun Pharma, Torrent, and Dr. Reddy's have launched affordable semaglutide, a groundbreaking weight-loss drug, following Novo Nordisk's patent expiry. This move significantly reduces therapy costs, offering patients greater access to treatment for obesity and type-2 diabetes. torrent pharma even introduced both oral and injectable versions, marking a significant step in addressing India's growing metabolic disorder crisis.

As semaglutide’s patent expires on March 20 the entry of generics is set to nearly halve treatment costs, opening up injectable anti-obesity treatment. But pharma firms, trying to stand out in a crowded room, are looking beyond simple price cuts, eyeing an entire weight-loss ecosystem. This could include diet plans, counselling and clinic partnerships

Third generation leadership gets into drugmaker torrent pharma as its board clears the appointment of Aman Mehta as whole-time director. Aman, 30, is the son of Samir Mehta, chairman of the pharma company, the flagship of the $3-billion, Ahmedabad-based Torrent Group.

Homegrown pharma major, torrent pharmaceuticals Limited posted Rs 287 crore in profit for the fourth quarter of the fiscal year 2022-23, the company said on Tuesday in its stock exchange filing. torrent pharma posted a net loss of Rs 118 crore during the corresponding period.

Third-generation leadership has begun taking charge at drugmaker torrent pharma with its board clearing the appointment of Aman Mehta, 30, the son of Samir Mehta, chairman of the company, as whole-time director.

The tribute couldn't have been better for Torrent group founder late UN Mehta, who passed away on the same day in 1999.

torrent pharmaceuticals Ltd’s consolidated net profit declined by 16% at Rs 249 crore for the quarter ended December, 2021 due to the muted performance in the US market. The company had registered a net profit of Rs 297 crore during the third quarter of the previous fiscal.

torrent pharma's acquisition of JB Chemicals & Pharmaceuticals propels it to become India's fifth-largest pharmaceutical company, capturing a 4.6% market share. This deal significantly strengthens Torrent's position in the cardiac therapy market, overtaking Sun Pharma with nearly 11% share. The acquisition boosts Torrent's presence in key therapeutic areas, with consolidated revenues exceeding Rs 15,000 crore.

torrent pharmaceuticals Limited is an Indian pharmaceutical company that ranked 8th in the Indian pharmaceutical market on Wednesday. The company announced a 14% rise in its consolidated net profit for the third quarter of fiscal year 202223. The company's gross revenues grew from Rs 2108 crore to Rs 2491 crore during the period. torrent pharma said in its regulatory filing that its India revenues stood at Rs 1259 crore and grew 17 after including revenue from integration of Curatio Healthcare revenues from other countries grew 18 with US Rs 291 crore revenue during Q3 and Brazil Rs 248 crore businesses posting the highest 24 and 36 growth in revenues respectively. According to AIOCD's secondary data, torrent pharma's growth for the quarter was 12 which was in line with that of the Indian pharma market at 12. The company's stock price closed at Rs 155750 per share as the markets closed on Wednesday down 186 against the previous close. The pharma giant which has expanded its field force too with a total of 5300 medical representatives including Curatio divisions.

torrent pharmaceuticals Ltd on Monday announced acquisition of two brands in women healthcare segment from global pharma player Novartis AG, Switzerland.

Private equity firm ChrysCapital has invested around $40 million in drug company torrent pharma, expanding its portfolio of healthcare companies and taking up the total exposure in the sector to nearly $300 million.

Gujarat-based pharmaceutical major, torrent pharmaceuticals on Tuesday announced it will acquire dermatology firm, Curatio Healthcare (I) Private Limited for Rs 2,000 crore. The companies have entered into a definitive agreement paving the way for Torrent’s 100% acquisition of Curatio. The transaction is subject to conditions precedent and is expected to close within one month.

torrent pharma is set to acquire a controlling stake in JB Chemicals & Pharmaceuticals for approximately Rs 18,000 crore, marking the second-largest pharma deal in India. The acquisition involves purchasing a 46.4% stake from KKR, followed by an open offer to public shareholders. This deal will create India's second most valued pharma company, with substantial revenue and a top-five ranking.